Namzaric™ is a once-daily, fixed-dose combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Donepezil is the active ingredient in ARICEPT® (donepezil hydrochloride), which is indicated for the treatment of mild to severe dementia of the Alzheimer’s type. Namzaric™ is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil HCl once daily.
Allergan owns the exclusive U.S. commercialization rights, while Adamas has the right to develop an extended-release version of memantine and a fixed-dose combination of memantine and donepezil for ex-U.S. markets. Adamas is eligible to receive royalties from Allergan for U.S. sales of Namzaric™ beginning in May 2020.
Eligible to receive royalties on net sales of NAMZARIC® beginning in 2020.